LY294002 enhances cytotoxicity of temozolomide in glioma by down-regulation of the PI3K/Akt pathway

Treatment with the PI3K inhibitor LY294002 combined with temozolomide significantly suppressed tumor cell proliferation.

• The combination of LY294002 and temozolomide led to a higher rate of cell death compared to either treatment alone.
• Apoptosis-related proteins, cleaved-caspase-3 and Bax, were more significantly increased with the combination treatment.
• The invasive ability of glioma cells was reduced when treated with both LY294002 and temozolomide.
• Levels of p-Akt and Bcl-2, which are associated with resistance to temozolomide, were notably decreased by LY294002.
• These results indicate that LY294002 may enhance the effectiveness of temozolomide by inhibiting the PI3K/Akt pathway.

AI simplified